Anzeige
Mehr »
Login
Dienstag, 23.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Breaking News: InnoCan startet in eine neue Ära – FDA Zulassung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
374 Leser
Artikel bewerten:
(1)

ADM Tronics Unlimited, Inc.: ADM Tronics Reports First Quarter of Fiscal Year 2021 Results

NORTHVALE, NJ / ACCESSWIRE / August 19, 2020 / ADM Tronics Unlimited, Inc. (OTCQB:ADMT), a technology-based developer and manufacturer of innovative technologies and products, announces results for its first fiscal quarter ended June 30, 2020 of Fiscal Year 2021.

ADM Tronics' first fiscal quarter ended June 30, 2020 encompassed a full three-month period impacted by the effects of the COVID-19 pandemic. ADMT took aggressive steps to minimize disruption of operations by securing Essential Manufacturer exemption from the statewide shutdown. This allowed continued research, development and manufacturing operations, throughout the quarter, while encompassing CDC safety guidelines. The Company established clerical activities remotely.

By maintaining full operational capability, ADMT's electronic segment manufacturing revenues increased over 86% to $288,062 for the quarter ended June 30, 2020 as compared to $154,767 for the same period last year. This was offset by revenues in engineering and chemical segments, combined, of $281,031 as compared to $676,054 for the same period last year, a decrease of 58%.

"Due to the pandemic, our first quarter was extremely challenging. Although many businesses shutdown or severely curtailed operations, we were steadfast in our efforts to persevere," stated Andre' DiMino, President of ADM Tronics. "That allowed us to increase our electronics segment revenue by over 86% compared to last year's first fiscal quarter. However, due directly to the effects of the pandemic on our customers, both our chemical and engineering segments posted reductions in revenues. Maintaining our commitment of advancing our proprietary developments, such as our Sonotron technology, we continued to invest in research and development. We are confident that, as the world emerges from this crisis, the investments made in our R&D, as well as our customers resuming demand for our products and services, we expect multiple avenues for substantial growth."

Revenues for the quarter ended June 30, 2020 were $569,093 as compared to $830,821 for the same period last year, a decrease of 31%. Net loss for June 30, 2020 was $115,736 as compared to net income of $52,769 for June 30, 2019. Complete financial results are available in the Company's Quarterly Report on Form 10Q for June 30, 2020, available at www.sec.gov.

Financial Highlights

Three Months Ended Three Months Ended
June 30, 2020June 30, 2019
Net Revenues
$569,093$830,821
Cost of Sales
401,503396,009
Gross Profit
167,590434,812
Operating expenses:
Research and development
125,904145,766
Selling, general and administrative
219,780214,255
Depreciation and amortization
5,7765,506
Total operating Expenses
351,460365,527
Income (loss) from operations
(183,870)69,285
Total other income (expense)
13,6345,484
Income (loss) before provision for taxes
(170,236)74,769
Benefit (provision) for income taxes:
Current
12,500(1,000)
Deferred
42,000(21,000)
Total benefit (provision) for income taxes
54,500(22,000)
Net income (loss)
$(115,736) $52,769
Net income per common share
$(0.00) $0.00
Weighted average shares of common stock outstanding - diluted
67,588,50467,588,504

About ADMT

ADMT is a diversified, technology-based developer and manufacturer of innovative technologies and products. Its core competency is its ability to conceptualize a technology, bring it through development, into manufacturing and commercialization, all in-house. ADMT has three areas of activity: Proprietary Electronic Medical Devices; Design, Engineering, Regulatory and Manufacturing Services; and, Eco-Friendly, Safe, Water-Based Formulations. The Company's headquarters, laboratories, FDA-Registered medical device and manufacturing operations are located in Northvale, NJ. ADMT's multi-disciplinary team of engineers, researchers and technologists utilize advanced technology infrastructure, for the research, development and commercialization of diversified technologies. Additional information is available at admtronics.com

Except for historical information contained herein, the matters set forth in this news release are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995), including statements regarding future revenue growth and performance. Although ADMT believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. Factors that could contribute to such differences include those described from time to time in ADMT's filings with the SEC, news releases and other communications. The Company assumes no obligation to update the information contained in this news release.

Contact:
Andre' DiMino
201-767-6040
andre@admtronics.com

SOURCE: ADM Tronics Unlimited, Inc.



View source version on accesswire.com:
https://www.accesswire.com/602502/ADM-Tronics-Reports-First-Quarter-of-Fiscal-Year-2021-Results

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2020 ACCESSWIRE
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.